✅💊 Medication Overuse Headache (MOH) – chronic daily headache caused by frequent or excessive use of analgesics or migraine-specific drugs. ⚠️ Typically occurs in patients with pre-existing migraine or tension-type headache who escalate medication use → creating a cycle of dependency and worsening pain.

🔑 Primary Cause: Overuse of headache medications (analgesics, triptans, ergotamines, opioids).
👩‍⚕️ Commonly Affected: Patients with chronic migraine or tension-type headaches.

📋 Clinical Presentation

Key features of MOH:

📆 Headaches ≥15 days/month.
😣 Persistent, dull, daily headache (often present on waking).
💊 Temporary relief with analgesics → rapid recurrence → cycle of overuse.
🌀 Progression from episodic to chronic headache pattern.
⚡ Associated symptoms: mild nausea, photophobia, irritability, sleep disturbance.

🤔 Suspect MOH If:

✅ Headache ≥15 days/month in a patient with known migraine/chronic headache disorder.
✅ Regular overuse of acute headache drugs for >3 months:
- 💉 Ergotamines
- 💊 Triptans
- 🩹 Simple analgesics (paracetamol, ibuprofen, NSAIDs)
- 💊 Opioids or combination analgesics

🔎 Investigations

🖥️ Imaging (MRI/CT) is usually normal. Its main role is to exclude secondary causes of chronic headache. No specific biomarker exists for MOH → diagnosis is clinical.

Imaging: Normal (rule out tumour, raised ICP).
Blood tests: Only to exclude secondary causes if clinical suspicion (e.g., thyroid, renal, liver function).

🧾 Differential Diagnosis

🌩️ Migraine progression: Episodic → chronic without medication link.
🧠 Brain tumour: If neurological deficits, seizures, abnormal imaging.
👁️ Benign Intracranial Hypertension (BIH): Daily headache + papilloedema/visual symptoms.
💊 Other drug-induced headaches: e.g., nitrates, caffeine withdrawal.

🛠️ Management

Breaking the cycle of overuse and treating the underlying headache disorder is key.

Medication / Intervention	Indication / When to Start	Dosing / Notes	Monitoring / Side Effects	Contraindications / Cautions
Analgesic withdrawal	All patients with MOH; start immediately after diagnosis	Gradual taper or abrupt stop depending on drug type; may use bridging therapies	Transient worsening headache, nausea, sleep disturbance	Monitor for severe withdrawal symptoms; opioids may require inpatient supervision
Triptans / Ergotamine withdrawal	Patients overusing migraine-specific drugs; start after evaluation	Immediate discontinuation; supportive therapy (antiemetics, hydration)	Headache rebound, nausea	Caution in cardiovascular disease
Amitriptyline (TCA)	Preventive therapy for chronic tension-type or migraine background headache	Start 10–25 mg nocte; titrate to 50–75 mg as tolerated	Sedation, dry mouth, constipation, weight gain	Cardiac conduction defects, glaucoma, severe urinary retention
Beta-blockers (Propranolol)	Migraine prophylaxis after withdrawal complete	Start 40 mg BD, titrate to 160 mg/day	Fatigue, bradycardia, hypotension	Asthma, severe bradycardia, heart block
Topiramate / Valproate	Migraine prophylaxis in selected patients	Topiramate: 25–50 mg/day titrate to 100–200 mg; Valproate: 500–1500 mg/day	Weight loss, paraesthesia (topiramate); tremor, hair loss, hepatotoxicity (valproate)	Pregnancy (valproate), kidney stones (topiramate)
CGRP inhibitors (erenumab, fremanezumab)	Refractory chronic migraine after MOH withdrawal	Monthly subcutaneous injections per product guidelines	Injection site reactions, constipation	Limited long-term safety data; avoid in pregnancy
Behavioural / non-drug therapy	All patients; adjunct to withdrawal and prophylaxis	Cognitive-behavioural therapy, headache diaries, lifestyle modification	Safe, non-pharmacological	None

🎓 Patient Education & Follow-Up

Explain MOH cycle: overuse → rebound → chronic headache.
Stress long-term medication reduction, sleep hygiene, hydration, exercise, and stress management.
Regular follow-up essential to prevent relapse; consider behavioural therapy or specialist headache clinic referral.

💡 Exam Pearl: Think MOH when: “Daily headaches + analgesic overuse + normal imaging”. ✅ NICE-aligned guidance: NICE CG150 – Headaches in adults

📚 References & NICE Guidance

✅ NICE Clinical Guideline CG150 – Headaches in adults
Covers assessment, diagnosis, and management of primary and secondary headaches including MOH. Provides guidance on withdrawal strategies and prophylactic therapy.
✅ NICE Guideline NG197 – Headaches: diagnosis and management in children and young people
Includes MOH recommendations relevant to adolescents and links to adult headache guidance for context.
✅ NICE Quality Standard QS150 – Headaches in adults
Summarises key quality statements including assessment of analgesic overuse and structured follow-up.
📄 Headache Classification: International Classification of Headache Disorders (ICHD-3)
Defines criteria for MOH, migraine, tension-type headache, and secondary headaches.
🧠 Clinical Review: Diener HC et al., “Medication-overuse headache: epidemiology, pathophysiology and management,” CNS Drugs, 2019
Comprehensive review on MOH pathophysiology, risk factors, and treatment strategies.
🧪 Evidence-based review: Katsarava Z et al., “Management of medication overuse headache,” Headache, 2018

All guidance above is from NICE or internationally recognised headache sources, suitable for UK clinical practice and patient management.

The content on this website is provided for educational and informational purposes only to support exam preparation (e.g., MLA, MRCP, USMLE) and learning. This is NOT medical advice, diagnosis, treatment, or professional guidance. It does not replace consultation with a qualified healthcare professional, official guidelines (e.g., NICE, GMC, BNF), or supervised clinical practice. Always verify information with current, authoritative sources. Makindo and its contributors accept no liability for any reliance on this content, including errors, omissions, or any resulting harm, loss, or consequences. By using this site, you agree to these terms.

Headache - Medication Overuse Headache ✅